Alder BioPharmaceuticals, Transforming Migraine Treatment

Migraine affects more than 36 million Americans2 – over 70% of them women3 – and is considered the third most disabling disease in the world.2 Migraine is not just a headache; in fact, it affects the body’s entire nervous system, causing all the nerve endings to be on fire – the pain can be so excruciating that it becomes too painful to see, to hear or to brush hair. It stops a person from driving, picking up kids or getting out of bed, and it’s associated with other serious diseases such as depression, anxiety and irritable bowel syndrome.2 Migraine can last for decades, often during what should be the most productive years of an individual’s life.4

Migraine can remit or progress to chronic migraine over time and persist as chronic migraine for years or decades, but it commonly oscillates between periods of episodic and chronic migraine.4 Historically, preventive treatments for migraine have failed to meet the needs of most patients, and prior to anti-calcitonin gene-related peptides (CGRPs), many have discontinued treatment within six months to a year due to side effects and/or occurrence of side effects.5,6,7

There is a significant need for rapid, effective and well-tolerated treatment options for migraine prevention,8 particularly for patients who are highly impacted by their disease.

Robust Development Pipeline

Alder strives to design best-in-class therapies that address unmet medical needs and have the potential to transform the lives of millions of patients.

To view our comprehensive pipeline, click here


2. Migraine Research Foundation. Migraine Facts. Available at: Accessed May 20, 2019.

3. Migraine Research Foundation. Migraine in Women. Available at Accessed on March 26, 2019.

4. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015; 55(S2):103-122.

5. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.

6. Parsekyan D. Migraine prophylaxis in adult patients. West J Med. 2000;173(5):341-345

7. Hepp, Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):477-88.

8. Bigal ME, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009;49(7):1028-1041.